-
公开(公告)号：US08951525B2
公开(公告)日：2015-02-10
申请号：US13803887
申请日：2013-03-14
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: A61K39/395 , C07K16/46 , C07K16/36 , C07K16/28 , A61K39/00
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
-
公开(公告)号：US20140234304A1
公开(公告)日：2014-08-21
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos ALMAGRO , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US08999333B2
公开(公告)日：2015-04-07
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
-
Search Results
3
records
(took 0.014 seconds)
